These findings suggest that SAMiRNA-AREG nanoparticles represent an effective siRNA modality for intervention in renal fibrosis by downregulating the expression of AREG, fibrosis factors, and inflammatory cytokines. The gene discussed is AREG; the disease is renal fibrosis.